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Growth promoting effects of growth hormone and IGF-I are additive in
experimental uremia. Exogenous growth hormone (GH) stimulates the
endogenous production of IGF-I and improves growth in uremia. We
investigated whether exogenous IGF-I is also able to improve uremic
growth failure in rats and whether the growth promoting effects of GH and
IGF-I are additive. In female 150 g uremic (subtotal nephrectomy, NX)
Sprague-Dawley rats, both rhGH in doses from 2 X 1.25 to 2 X 10 lU/kg
bid s.c. and rhIGF-I in doses from 2 X 0.5 to 2 x 4.0 mg/kg bid s.c. caused
a dose-dependent increase in weight gain and length gain. However,
endogenous production of GH was suppressed by both agents. Peptide
hormone treatment did not affect cumulative food intake, but significantly
increased food efficiency ratio (weight gain/food intake). Concomitant s.c.
treatment with maximally effective doses of rhGH (12 X 5 lU/kg bid) and
of rhIGF-I (2 X 2 mg/kg bid) resulted in additive growth promoting effects
in NX and pair-fed control (CO) animals during the observation period of
12 days. Cumulative length gain was 3.2 0.5 cm in solvent-treated
NX-animals, 4.1 0.5cm with rhGH (+ 28% above solvent), 4.2 0.6cm
with rhIGF-I (+ 31%) and 4.9 0.5 cm with both peptides (+ 53%). The
food efficiency ratio was 0.16 0.05 in solvent NX, 0.33 0.04with rhGH
(+ 106% above solvent), 0.23 0.02 with rhIGF-I (+ 44%), and 0.38
0.02 with both peptides (+ 138%). Histomorphometric analysis and
measurements of length gain by fluorescence microscopy in the upper
tibial metaphysis confirmed the growth promoting effects of both peptide
hormones. The serum concentrations of IGF binding protein (BP)-4
(Western ligand blotting analysis) and of IGFBP-2 (immunoblot) were
increased in uremic animals whereas IGFBP-3 was unchanged. Treatment
with IGF-I and/or rhGH increased serum concentration of IGF-I but did
not change the IGFBP pattern. rhIGF-I lowered blood glucose levels
within one to two hours after injection. The effect was most pronounced
during the first treatment day and declined thereafter. Concomitant
treatment with rhGH attenuated the glucose lowering effect of rhIGF-I
(glucose serum concentration at day one: 120 11 mg% in solvent NX, 50
21 mg% with rhIGF-I, 80 24 mg% with both peptides). It is
concluded that: (i) IGF-I is able to stimulate growth in NX animals but
suppresses endogenous GH production in the long run; (ii) the concom-
itant treatment with IGF-I and GH has additive effects on growth; and (iii)
concomitant treatment with rhGH prevents hypoglycemia that is noted
with rhIGF-I alone.
Uremic growth failure has been identified to be at least in part
the consequence of secondary growth hormone insensitivity [1, 2].
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The tissue resistance to the physiological action of growth hor-
mone (GH) may be explained by reduced GH receptor expression
[3], reduced somatotrope binding sites [4], low activity of GH
binding protein [5] and low hepatic expression of insulin-like
growth factor-I (IGF-I) mRNA [6, Note added in proof]. In
addition, somatomedin bioactivity is diminished [2, 7] due to
increased binding of IGF-I to its binding proteins [2, 8, 9] which
accumulates in serum of the uremic organism. These changes
result in impaired IGF-I-dependent growth processes.
In experimental chronic renal failure [1] as well as in children
with chronic renal failure [7, 10] it is possible to stimulate growth
by daily injections of rhGH in supraphysiological amounts. Sup-
raphysiological doses of rhGH stimulated circulating IGF-I levels
to a higher extent than IGFBP-3 levels [7]. The improvement of
the relationship between IGF-I and IGFBP-3 resulted in a
normalization of the IGF bioactivity [7, 11].
If the reduced availability of IGF-I is a major reason for GH
insensitivity, one would expect that treatment with rhIGF-I might
improve uremic growth failure. This has recently been confirmed
[12]. On the other hand, IGF-I treatment may lead to serious side
effects like hypoglycemia and circulatory instability [13—16]. In
addition, high circulating levels of IGF-I may reduce pituitary GH
secretion [15, 17, 18].
The combined treatment with rhGH and rhIGF-I may prevent
some of the negative effects of a monotherapy with rhIGF-I.
Because GH seems to increase anabolism without affecting catab-
olism [19, 20] and because IGF-I may have a positive effect on
nitrogen balance by reducing catabolism [19, 21], an intensified
effect on growth may be expected from a combined treatment with
both peptides. In a recent experimental study in healthy animals,
we demonstrated that maximally effective doses of IGF-I and of
GH had additive effects on weight gain but not on length gain [22].
Although the additive effects of rhGH and rhIGF-I were dis-
cussed in a recent study for uremic animals [12], these studies are
not conclusive because the doses of each peptide used for
combined treatment were not maximally effective doses.
It was the aim of the present study to determine the maximally
effective doses of rhIGF-I and of rhGH for body growth of uremic
animals and to analyze whether the growth promoting effects of
both hormones are additive. Furthermore, the effects of both
peptides on glucose metabolism were evaluated.
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Methods
Animals
Female Sprague-Dawley (SD) rats (Charles River-Wiga, Sul-
zfeldlAllgau, Germany), weighing 120 to 150 g, were used for the
experiments. Female rats were chosen because of the better
response to growth hormone in female rats, as previously docu-
mented [1]. One week prior to the studies, the animals were
transferred to single cages at constant room temperature (24°C)
and humidity (70%) on a 12 hours on/12 hours off light cycle. The
diet contained 13,800 kJ/kg, 0.95% calcium, 0.8% phosphorus, 500
lU/kg vitamin D3 and 18% protein (wt/wt). With the exception of
pair-fed controls the animals had free access to food (Altromin C
1000, Altromin Company, Lage/Lippe, Germany) and deionized
water.
The animals were subjected to a two-stage subtotal nephrec-
tomy (NX) or sham-operation as described previously [23]. Sub-
total nephrectomy of the left kidney was performed one week
prior to surgical removal of the right kidney. At that moment, the
animals had a mean body wt of about 150 g. Control aninmals
(CO) were sham-operated (renal decapsulation). The CO group
was pair-fed as previously described [23].
Recombinant peptide hormones (rhGH and rhIGF-I) were
administered subcutaneously twice daily, in doses indicated under
protocols. RhGH (Genotropin) and rhIGF-I (lot No. 77135/51)
were provided by Pharmacia AB (Stockholm, Sweden).
Protocols
Dose response experiments. For dose response experiments, NX
animals of 140 to 150 g were used. All animals were allowed free
access to food and water. For determining the maximum dose of
rhGH, groups of six animals each were injected with 0, 2.5, 5.0,
10.0 and 20.0 IU rhGH/kg daily in two divided doses s.c. during a
period of ten days. For determining the maximum growth simu-
lating effect of rhIGF-I, six animals per group were injected s.c.
with 1, 2, 4, and 8 mg/kg/day in two divided doses during a period
of ten days.
Experimental protocol for concomitant treatment with rhGH and
rhIGF-I. The animals were randomized into four groups. Group A
received solvent twice daily s.c. during 12 days, Group B received
2 x 5 IU rhGH/kg daily s.c., Group C received 2 X 2 mg
rhIGF-I/kg daily s.c., Group D was injected with rhGH and
rhIGF-I in doses indicated above. All groups (A, B, C, D) were
additionally divided into two subgroups of nine animals each:
uremic animals (NX) and sham-operated pair-fed control animals
(CO).
Analytical techniques
In vivo measurements. Body weight was measured during the
afternoon in non-fasting animals. Food intake was measured daily
and food conversion ratio was calculated from cumulative food
intake and cumulative weight gain [11. Nose-to-tail-tip distances
were measured in anaesthesized animals and under complete
muscle relaxation as described previously [231.
Organ weight
The animals were sacrificed by aortic puncture under general
anaesthesia (100 mg/kg Ketanest, Park Davis Company, Berlin,
Germany, and 10 mg/kg Valium, Hoffmann La Roche, Grenzach-
Wyhien, Germany). Organs were weighed before and after des-
iccation (24 hr; 80°C in the presence of desiccant).
Biochemical measurements
Blood was obtained by aortic puncture from non-fasted animals
at the end of the experiment, which was 14 to 15 hours after the
last injection of peptide hormones. A 24-hour urine sampling was
performed in a metabolic cage during the last 24 hours of the
experiment. Serum and urine biochemistry were analyzed using a
multichannel autoanalyzer (Beckmann Synchron CX7, Germany).
Creatinine was determined by a kinetic method according to Jaffé
without deproteinization; the within assay coefficient of variation
was < 3%. Serum glucose concentration was determined photo-
metrically using a Refioton analyzer (Boehringer, Mannheim,
Germany). The within measurement coefficient of variation was
<3%. For these measurements blood was taken from the tail vein
on day 1 immediately before the first injection of rhIGF-I, and
one and two hours, respectively, thereafter. The measurements
were repeated on day 11 before as well as one and two hours after
the 21st injection.
Hormonal measurements
Measurements of insulin was performed by RIA as described
earlier [24]. Measurements of rhGH and of rhIGF-I were done by
RIA techniques as described earlier [7, 25]. The antibody' for
IGF-I determination was provided by Professor Peter Gluckman
(New Zealand), and the standard preparation was recombinant
hIGF-I (rhIGF-I; Pharmacia AB, Stockholm, Sweden). 1251.
iodinated rhIGF-I was used as a tracer. The cross reactivity with
rat IGF-I was more than 90%. Rat GH was determined using a
RIA technique [25]. Antibodies against rGH and a standard
preparation of rGH (RP-2) were supplied by the National Hor-
mone and Pituitary Program (Bethesda, MD, USA). Rabbit
anti-monkey serum was prepared at Pharmacia AB, and rhGH for
labeling was donated by Professor Paul Roos (Uppsala, Sweden).
Incubation was performed at + 4°C, initially with samples (in
duplicate; intrassay Cv 2 to 8% for GH levels between 0,5 to 8
ng/ml) or standards together with primary antibodies overnight,
followed by incubation with labeled rGH for a further 16 hours.
The complexes were precipitated by second antibodies and cen-
trifuged. The pellets were counted in a LKB-Wallac Gamma-
counter. Concentrations were calculated. The standard curve
ranged from 0.25 to 16 ng/ml.
Serum IGFBP-3 and IGFBP-4 were determined by Western
ligand blotting performed according to the method of Hossenlopp
et al [26] with slight modifications [27]. Two microliters of serum
were processed by electrophoresis for five hours at 170 mV on
SDS/15% polyacrylamide slab gels (15 x 15 X 0.15 cm) under
non-reducing conditions (except the 14C-labeled molecular weight
markers; Rainbow marker, Amersham, UK). After electroblotting
on nitrocellulose, membranes were processed as described in Zapf
et al [27].
IGFBP-2 was identified by immunoblotting with IGFBP-2
antiserum: 20 d of pooled serum of uremic and pair-fed normal
rats were processed by electrophoresis on SDS/15% polyacryl-
amide gels (15 X 15 X 0.15 cm) under non-reducing conditions
and transferred to Hybond C-Super Membranes (Amersham,
UK) by electroblotting for two hours at 0.5 A. Membranes were
processed according to the protocol for ECL Western blotting
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provided by Amersham. Rabbit anti-rat IGFBP-2 antiserum (pro-
vided by Dr. D. Clemmons, Chapel Hill, NC, USA) was used at
1:10,000 dilution and goat anti-rabbit IgG antiserum diluted
1:2000 was used as second antibody.
Histomorphometric analysis of proximal tibia
The proximal tibia growth zone was used for morphometric
analysis. Five days prior to sacrifice, the fluorescent marker
calcein was administered to animals in a single injection (15 mg/kg
s.c.) [28]. The tibia was fixed in 4% formaldehyde with 0,1 M
sodiumcacodylate-buffer at a pH of 7.4 for several days. It was
then washed with H20 and dehydrated in 70% ethanol (vol/vol) at
4°C for 24 hours; dehydration was completed in a graded series of
ethanol at + 20°C. Thereafter, tissue slices were embedded in
methylmethacrylate and polymerization executed at + 30°C. Five
micrometer-thick sections were cut in frontal planes on a Jung
microtome No. 1140. Sections were subsequently mounted on
gelatin-coated glass slides and stained initially by the von Kossa
reaction and subsequently with McNeill Tetrachrome [29] for
morphometric estimation of growth plate height. Ten micrometer
sections from each tibia, also mounted on glass slides, were used
unstained for measurements of growth rates using incident light
fluorescence microscopy [30].
Statistical analysis
Data are given as means SD if not indicated otherwise. Data
were examined for normal and non-Gaussian distribution by the
Shapiro-Wilk test [31]. For comparison between two normally
distributed groups, unpaired Student's t-test (two-tailed) was
used. For comparison of more than two normally distributed
groups, one way ANOVA followed by pairwise multiple compar-
isons (Student-Newman-Keuls method) was used. For non nor-
mally distributed data, the non-parametric Kruskal-Wallis test,
followed by all pairwise multiple comparison (Dunn's method),
was used. P < 0.05 was accepted as statistically significant.
Results
Dose response experiments in uremic animals
Increasing doses of rhGH and rhIGF-I increased length gain
and weight gain stepwise (Fig. 1). The maximally growth stimu-
lating effect for length gain and weight gain in NX animals was
obtained by injecting 4 mg rhIGF-I/kg in two divided doses s.c.
daily and by injecting 10 IU rhGH/kg/day in two divided doses s.c.
Concomitant treatment with rhIGF-I and rhGH
Based on the dose response experiments, maximally growth
promoting doses of rhIGF-I (2 x 2 mg/kg/bid) and rhGH (2 X 5
lU/kg/bid) were injected separately and concomitantly to NX
animals and sham-operated CO animals (N = 9 animals per
group). Cumulative weight gain in solvent treated NX animals was
significantly less than in CO animals (Table 1). During the
observation period of 12 days, peptide hormone treatment con-
tinuously improved both length gain and weight gain of NX
animals and of CO animals (Fig. 2). The effect of rhGH on length
gain was similar to the effect of rhIGF-1 whereas the rhGH effect
on weight gain was significantly greater. If both peptides were
given concomitantly their growth promoting effects were nearly
additive. Neither rhIGF-I nor rhGH increased the cumulative
food intake of NX animals to a major extent. In contrast, the food
efficiency ratio was significantly increased by rhGH and by con-
comitant treatment.
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Fig. 1. Growth response for weight gain and
length gain in uremic rats following treatment
with rhGH and with rhIGF-I. Dose response
curves. Increasing doses of rhIGF-I
administered for 10 days had increasing effects
on length gain (A) and weight gain (B);
maximal effects were obtained with 4 mg/kg/day
administered in two doses s.c. per day. RhGH
administered for 10 days had also increasing
effects on cumulative length gain (C) and
weight gain (D); maximal effects were obtained
with 10 lU/kg/day given in two doses s.c.
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Table 1. Effect of 4 mg/kg/day rhIGF-I and 10 lU/kg/day rhGH given separately or concomitantly for 12 days on growth in uremic
and pair-fed rats
Cumulative food
intake g Food conversion ratio
Muscle (triceps surae)
wet weight g
Cumulative weight gain
g
Cumulative length gain
cm
Uremia (N = 9)
Vehicle 166 isa 0.16 0.05° 1.34 0.07a 27.3 10.2c 3.2 0.5
rhIGF-I 172 23C 0.23 0.02c (+ 44%) 1.36 0.06a 39.0 10.1° (+ 43%) 4.2 0.6 (+ 38%)
rhGH 166 23C 0.33 0.04° (+ 106%) 1.42 o.lla 57.6 13.4° (+ 111%) 4.1 0.5 (+ 28%)
rhIGF-I + rhGH 181 ioa 0.38 0.02° (+ 137%) 1.53 0.07 68.9 5.0 (+ 152%) 4.9 0.5 (+ 53%)
Pair-fed (N = 9)
Vehicle 166 15C 0.28 0.03a 1.32 o.lla 47.6 8.7a 3.4 0.5
rhIGF-I
rhGH
rhIGF-I + rhGH
172 23C
166 23C
181 ioa
0.31 0.04 (+ 11%)
0.43 0.03 (+ 54%)
0.47 0.03 (+ 68%)
1.43 0.05a
1.50 0.l0
1.56 0.O9'
54.9 8.5a (+ 15%)
71.9 9.1 (+ 51%)
84.7 8.2 (+ 78%)
4.1 0.4 (+ 20%)
4.1 0.6a (+ 20%)
4.7 0.5 (+ 38%)
Food conversion ratio is the cumulative weight gain (g)/cumulative food intake (g).
P values are from one way ANOVA followed by all pairwise multiple comparison (Student-Newman-Keuls method).
ab Significant differences between treatments within one experimental group (uremia or pair-fed); values sharing common superscripts are not
significantly different, while values without common superscripts are significantly different
C Significant differences between uremia and the respective treatment group in pair-fed animals
The striking effect of the combined treatment with rhIGF-I and
rhGH on skeletal growth was confirmed by the micromorphomet-
nc analysis of the upper tibial metaphysis (Fig. 3A). In NX
animals, the height of the epiphyseal plate was significantly
increased by rhGH whereas the effect of rhIGF-I alone was only
modest. Combined treatment with both peptides increased the
height of epiphyseal plate significantly more than the treatment
with rhGH or rhIGF-I alone. The growth rate per day was
analyzed after s.c. injection of the fluorescence marker calcein five
days prior to sacrifice. Measuring the distance from the calcifica-
tion front to the calcein front within the primary spongiosa was
taken as a marker of growth during the last five days of the
experiment. In uremic animals, the growth rate with the combined
treatment was significantly higher than with rhIGF I or rhGH
alone. It is of note that rhIGF-I alone did not improve growth rate
significantly.
Analysis of the histological changes of the growth plate in
uremic animals documented an enlargement of the growth plate,
which resulted from an inrease in cell number and cell size of all
cell types of the proliferative and the hypertrophic cells including
the cells of the calcified zone (Fig. 3B).
In parallel to the increase of body wt, the muscle weight of
triceps surae increased under the influence of rhIGF-I and rhGH.
The parallel increase of muscle wet wt and muscle dry weight gave
evidence that the peptide hormones did not increase the water
content out of proportion in these organs. In contrast, the ratio of
dry weight over wet wt of the liver decreased slightly but signifi-
cantly with the combined treatment, indicating that the water
content was increased by about 2% in comparison to solvent
treated animals.
Relevant biochemical and hormonal data are seen from Table
2. Serum creatinine was slightly increased in peptide hormone
treated uremic animals but not in pair-fed controls. Peptide
hormone treatment increased serum protein concentration in
uremic but not in pairfed control animals. There was no change of
urinary calcium excretion, whereas urea excretion decreased with
each of the hormones. This effect was most expressed with the
combined treatment. There was a tendency of increased protein
excretion with the combination of rhIGF-I and rhGH treatment.
When endogenous GH was measured by a specific rat RIA, it
became clear that the serum concentration of endogenous GH
was significantly lower during treatment with both rhGH and
rhIGF-I (Table 2). At the end of the experiment, IGF-I serum
concentration was significantly increased with rhGH but not with
rhIGF-I treatment. However, it has to be noted that blood
samples were obtained at variable time points (14 to 19 hr) after
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Fig. 3. A. Light micrographs of proximal tibial growth plate. Thick sections (5 jtm) of methylmetacrylate embedded proximal tibia! growth plate. Staining:
von Kossa and McNeil Tetrachrome. The growth plate heights of the two control groups (A and B) do not differ significantly, whereas the growth plate
heights of uremic animals treated with rhIGF-I and of uremic animals treated with rhIGF I plus rhGH are significantly higher than those of the controls.
Growth plate height increments are based both on largening of the proliferative zone height (to a major degree) and on an enlargement of the
hypertrophic zone height (maturation, hypertrophy and mineralization zone). Abbreviations are: E, epiphyseal bone tissue; P, proliferating zone; H,
hypertrophic zone; M, mineralization zone; arrowhead, mineralization front; horizontal arrow, vascular invasion front. Bar 100 j.m.
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Fig. 3. B. Micromorphometric analysis of
growth zone and of growth rate in uremic
animals treated with peptide hormones. Five
jm thick sections embedded in
methylmetacrylate were used for measuring
growth plate height and 10 m sections for
measurements of growth rates using incident
light fluorescence microscopy. Width of growth
zone and growth rate were significantly more
increased with combined treatment than with
rhIGF-I or rhGH alone. Data are given as
mean SEM. *Significant versus vehicle;
#significant versus the other treatment
modalities.
Table 2. Serum and urine (U) biochemistry in uremic and pair-fed control rats treated with rhGH, rhIGF-I or a combination of both for 12 days
Creatinine Urea Protein Phosphate
mg/dl giliter mmol/liter
GH ng/ml IGF-I
(rat assay) ng/ml
Insulin
U/ml
U-Urea
mg/IOU gid
U-Calcium
mmol!100 g/d
U-Protein
mg/lOU gid
Uremia
(N =9)
Vehicle 0.64 0.10"' 86.7 130abd 49.4 25ad 2.38 0.20a 14.6 6.9 937 78"' 22.6 2.7' 288 33a1 0.03 0.01 12.7 8.0'
rhIGF-I 0.71 010"" 93.0 19.7" 55.2 2.3" 2.96 021b 6.3 4.1 1220 75"' 16.3 23ad 275 3T 0.02 0.01 17.0 8.7"'
rhGH 0.71 013ahd 80.8 189ad 53.1 1.7"' 3.40 0.39" 2.8 4.1 1267 72bd — 202 34hd 0.02 o.ola 17.6 122""
rhIGF-I 0.79 010bd 101 188,d 56.3 24b 345 0.37" — 1121 64"" 15.9 23ad 168 48"' 0.02 o.ola 27.7 13.3"
+ rhGH
Pair-fed
(N =9)
Vehicle 0.32 0.07" 35.1 9.8" 55.0 4.1" 2.69 0.24" 11.3 4.2 840 28" 33.1 3.8" 356 51 0.03 0.02" 5.89 1.5"
rhIGF-I 0.31 0.03" 30.0 3.4" 55.6 1.8" 2.90 0.22" 5.8 39" 861 40" 31.3 35" 254 52" 0.02 0.02" 5.89 3.0"
rhGH 0.29 0.04" 28.3 59a 55.0 3.0" 3.03 0.22a 1.4 1.2" 1001 84" — 255 34" 0.02 0.01' 5.30 1.0'
rhIGF-I 0.31 0.03a 29.6 8.1" 55.4 5.Oa 3.35 0.27" — 1035 68" 27.2 3.4 235 42" 0.04 0.02" 6.70 2.2"
+ rhGH
P values are from one way ANOVA followed by all pairwise multiple comparison (Student-Newman-Keuls method).
bCSignificant differences between treatments within one experimental group (uremia or pair-fed); values sharing common superscripts are not
significantly different, while values without common superscripts are significantly different
d Significant differences between uremia and the respective treatment group in pair-fed animals
the last hormonal injection, because the animals could not get
sacrificed all at the same time.
Measurement of IGFBPs by Western ligand blot did not show
a difference for IGFBP-3 between uremic and Co animals (Fig.
4A), whereas an increased activity for glycosylated (30 kDa band)
and non-glycolysated (24 kDa band) IGFBP-4 was noted in
uremic serum. By immunoblot, an increased staining for IGFBP-2
was noted in uremic animals (Fig. 4B). Treatment with rhGH and
rhIGF-I did not influence these patterns.
Recombinant rhIGF-I had a major lowering effect on serum
glucose concentration when measured one and two hours after the
first injection (Table 3). This effect was significantly diminished if
rhGH was injected concomitantly. When the effect of rhIGF-I was
measured after the 21st injection on day 11, the glucose lowering
effect of rhIGF-I was still present in uremic but not in control
animals; however, it was much less expressed than on day 1.
Again, concomitant injection of rhGH counterbalanced the effect
of rhIGF-I. Serum insulin concentration was only measured at the
end of the experiment at non-defined time points after the last
hormonal injection in non-fasted animals according to the sacri-
fice protocol. This may be the reason why no systematic change
for insulin was noted in uremic and control animals (Table 2).
Discussion
The present study demonstrates that both rhGI-T and rhIGF-I
are able to improve growth in uremic rats in a dose-dependent
way. Whereas maximally effective doses of rhIGF-I (4 mg/kg/day)
and of rhGH (10 lU/kg/day) were equally effective on length gain,
the effect on weight gain was higher with rhGH. This is the first
report demonstrating that the effects of rhGH and rhIGF-I on
length gain and weight gain are additive in uremic rats. This
implies that IGF-I and GH improve growth, at least in part, via
different mechanisms.
It is already known that the combination of rhGH and rhIGF-I
treatment in rats [12] and humans [32] is substantially more
anabolic than therapeutical doses of rhIGF-I or rhGH alone. In a
recent paper, Hazel et al [121 could demonstrate that the en-
hancement of somatic growth in uremic rats was of great thera-
peutic significance if they used a combination of 1.7 mg rhIGF-I/
kg/day and 5.6 IU rhGH/kg/day. Because they did not use
maximally effective doses of both rhGH and of rhIGF-I, they
could not decide whether the effects of rhGH and of rhIGF-I were
indeed additive, because they could not exclude that increasing
doses of either rhIGF-I or rhGH alone would have achieved the
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Table 3. Effect of 2 mg/kg rhIGF-I and 5 lU/kg rhGH on serum
glucose concentration measured one and two hours after s.c. injections
Experimental groups
Before
injection
1 Hour
after
injection
2 Hours
after
injection
Day 1 (1st injection)
Uremia
rhIGF 120 11.3a 51.2 13.7a 49.2 21.6a
rhIGF + rhGH 122 15.5a 56.5 9.1 81.3 24.7"
Pair-fed
rhIGF 121 12.2a 44.1 8.5a 35.9 7.6C
rhIGF + rhGH 124 20.2C 43.6 7.Oa 89.2 16.7"
Day 11(21st injection)
Uremia
rhIGF 123 95C 737 15.3" 123 29.9
rhIGF + rhGH 119 73C 111 7.8 115 15.0
Pair-fed
rhIGF 135 13.5a 114 l9.7'" 117 7.5
rhIGF + rhGH 123 16.4C 119 l9.2 121 5.1
P values are from one way ANOVA followed by all pairwise multiple
comparison (Student-Newman-Keuls method).Ch Significant differences between treatments within one experimental
group (uremia or pair-fed); values sharing common superscripts are not
significantly different, while values without common superscripts are
significantly different
C Significant differences between day 1 and the respective treatment
group on day 11
In an earlier study in healthy female SD rats [22], we have
demonstrated that maximally effective doses of rhGH and
rhIGF-I were additive on weight gain; however, the combined
treatment did not result in additive effects on length gain. It is
possible that in the healthy ad libitum fed animals growth was
already maximally stimulated by a high dose of one of the two
— 0 a hormones and could not be further stimulated by the addition of
the second hormone. In a situation of reduced growth velocity
induced by uremia and/or reduced food intake (pair-fed controls),
rhIGF-I and rhGH obviously have additive effects.
In the past, it has been assumed that all effects of IGF-I can be
mimicked by GH treatment, which enhances the endogenous
production of IGF-I. Growth plate chondrocytes express the
growth hormone receptor [33, 34], and it has been speculated that
GH acts selectively upon resting stem cells as a differentiation
factor [35], the ensuing effect on proliferation being triggered by
local production of IGF-I, that is, by an autocrine/paracrine
mechanism (dual effect theory [35, 361). In contrast, in vivo studies
a of Hunziker et al gave strong evidence that IGF-I is also able to
stimulate stem cells [37]. In their studies both IGF-I and GH were
found to stimulate all phases of chondrocyte differentiation, but
IGF-I was less effective than GH. Our present study, demonstrat-
ing that GH increases length gain in addition to the maximal effect
of rhIGF-I, suggests that in the uremic condition GH itself, in
addition to circulating and locally produced IGF-I, can contribute
to chondrocyte maturation and thus to skeletal growth.
The observed additive increase in the food efficiency ratio by
both peptides without a major effect on the cumulative food
intake is consistent with an increase in nitrogen balance, which
was not directly measured. This is further supported by the
observation that urea excretion rate decreased under the influ-
ence of both peptide hormones without a change in serum urea
concentration. It is of interest that the maximal increase in the
food efficiency ratio above baseline was two times higher with
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Fig. 4  4 ' 1-labeled JOF-JI lig    fro  r i  left
panel) and control rats (right panel). Abbreviations are: I, treatment with
rhIGF-I; G, treatment with rhGH; IG, combined treatment. The 42/45/49
kDa triplets represent IGFBP-3. There is no difference between uremic
and control animals and treatment with peptide hormones did not result
in a significant change. For IGFBP-4 (24 kDa nonglycosylated and 30 kDa
glycosylated) an increase of radioactivity was noted in uremic serum. B.
Immunoblotting of pooled sera from uremic (U) and pairfed control rats
(P) with IGFBP-2 antiserum. There was a two- to threefold increase of
staining intensity for IGFBP-2 in uremic animals.
same improvement in growth as the combined treatment they had
used. The same argument holds for the investigations of Kupfer et
al in human [32].
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rhGH than with rhIGF-I. Horber and Haymond have shown that
rhGH treatment in healthy humans results in a positive protein
balance by increasing protein synthesis whereas it did not influ-
ence the rate of protein catabolism [20, 38, 39]. In contrast,
rhIGF-I appears to improve nitrogen balance by reducing protein
breakdown without major effects on protein synthesis [19, 20]. If
this is correct, both mechanisms may explain, at least in part, the
additive effects of rhIGF-I and rhGH in nephrectomized and
pair-fed CO animals in the present study. Exact measurements of
the lean body mass were not performed; however, it is not very
likely that an increase in total body water contributed to weight
gain to a major extent. Whereas the relative amount of tissue
water was unchanged by either hormone treatment for skeletal
and heart muscle, the water content of liver increased slightly by
0.9% with rhGH and by 2% with combined rhGH and rhIGF-I
treatment. The increase in total body water is much less than the
total increase in body wt.
Recombinant hGH treatment increased slightly but signifi-
cantly the serum IGF-I concentration. In animals injected with
rhIGF-I, serum IGF-I concentration had returned to baseline 14
to 19 hours after the last injection. Ligand blotting and immuno
blotting showed an increase of IGFBP-4 and IGFBP-2 in uremic
serum (measured for the first time in uremic rats), whereas
IGFBP-3 was unchanged. The increase of IGFBPs is analogous to
the reported increased serum concentration of IGFBP-1, -2 and -3
in uremic children [40—42]. Treatment with peptide hormones did
not change the pattern of binding proteins within the observation
period of 12 days. Thus, the increase in IGFBP in uremic animals
and the improvement of growth by exogenous IGF-I are compat-
ible with the hypothesis that increased IGFBPs act as growth
inhibitors in uremia [7, 8, 11, 42].
Analysis of growth rate by histomorphometry of the upper tibia
metaphysis showed a minor stimulation of growth rate by rhIGF-I
than recorded by the total body measurements. The histomorpho-
metric analysis reflected the growth rate only for the last five days
of the experiment (after staining for immunofluorescence). The
discrepancies might therefore be explained by the different time
intervals and/or differential effects of IGF-I on nose to tailtip
length and on metaphyseal growth at the upper tibia, respectively.
Another explanation might be the reduced endogenous produc-
tion of GH following the treatment with rhIGF-I (Table 2) also
observed in humans, such as in Laron dwarfism [17]. As a
consequence, the effect of rhIGF-I on growth may decrease with
time. In this respect, monotherapy with rhIGF-I may not be an
ideal treatment for uremic growth failure. In humans, a variety of
adverse events such as hypoglycemia and circulatory instability
further limit IGF-I monotherapy, at least in high doses [13—16]. In
our earlier rat experiments, most uremic but not control animals
died within the first day of high-dose rhIGF-I treatment [43]. Our
present investigations suggest that these animals may have died
because of hypoglycemia. Measurements before, one and two
hours after the first injection of rhIGF-I documented a drastic fall
of blood glucose concentration.
As in the report of Hazel et al [12], rhGH did not increase
serum glucose concentration but attenuated the hypoglycemia
induced by IGF-I when given concomitantly. This was also
reported for healthy volunteers [31]. Our results give the addi-
tional information that the potency of IGF-I to lower blood
glucose levels decreases with time. After 11 days of treatment,
only a minor reduction of serum glucose concentration was
observed one hour after rhIGF-I injection (Table 3). Even after
this time, the effect in uremic animals was more pronounced than
in CO animals. These observations may explain in part the clinical
observation that the adverse events of rhIGF-I in Laron dwarfism
can be prevented to a certain extent if the starting dose of rhIGF-I
is low and will be gradually increased to the final therapeutical
doses [17]. The reason for the adaptation of the organism to
exogenous IGF-I is not well understood and remains to be
clarified. From experimental [44] and clinical studies it is expected
that IGF-I treatment decreases insulin production. In the present
experiments, we were not able to analyze how insulin production
was influenced by rhIGF-I, since we measured serum insulin
concentrations only at the end of the experiments, that is, 14 to 19
hours after the last injection of rhIGF-I.
In conclusion, it is possible to treat uremic growth failure and
uremic growth hormone insensitivity in rats with rhIGF-I. How-
ever, the use of this peptide hormone is limited by the suppression
of endogenous growth hormone secretion and by adverse events,
such as hypoglycemia. When rhGH is given concomitantly with
rhIGF-I to uremic animals, the growth promoting effects of both
peptide hormones are additive and the hypoglycemia induced by
rhIGF-I is attenuated. Since the combined treatment with
rhIGF-I and rhGH seems to be safe and more effective than the
treatment with rhGH alone, the combined treatment with both
peptide hormones may become a new treatment modality for
uremic growth failure also in humans.
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